https://charts.traderzeitung.de/phases/IL0010941198 string(1382) "{"isin":"IL0010941198","name":"Kamada Ltd","stock_id_xnas":7872943,"stock_id_xnys":null,"generated_at":"2026-09-24 01:31:00","days":[{"date":"2026-09-21","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":null,"close_at":null,"complete":true,"perf_pct":null},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":8.75,"close_at":"2026-09-21 21:59:00","complete":true,"perf_pct":null},{"phase":3,"label":"post","from":"22:00","to":"26:00","close":null,"close_at":null,"complete":true,"perf_pct":null}]},{"date":"2026-09-22","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":null,"close_at":null,"complete":true,"perf_pct":null},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":8.855,"close_at":"2026-09-22 21:59:00","complete":true,"perf_pct":1.2},{"phase":3,"label":"post","from":"22:00","to":"26:00","close":null,"close_at":null,"complete":true,"perf_pct":null}]},{"date":"2026-09-23","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":null,"close_at":null,"complete":true,"perf_pct":null},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":8.78,"close_at":"2026-09-23 21:59:00","complete":true,"perf_pct":-0.847},{"phase":3,"label":"post","from":"22:00","to":"26:00","close":null,"close_at":null,"complete":false,"perf_pct":null}]}]}"

Kamada Aktie News & Nachrichten

[WKN: A0JMEX | Symbol: KMDA]

Realtimekurs

Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, the Proprietary Products segment and the Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.

10J

Alles

Vorbörsliche Indikationen

Regulärer Handel

Nachbörslicher Handel

Artikel aus der Redaktion der Trader-Zeitung

Es konnten keine Nachrichten über Kamada gefunden werden.

Kamada Nachrichtenticker öffnen

MT Newswires 17.09.2026 13:55 Uhr

Kamada hält bei steigender Zahl von Tollwut-Expositionen in den USA ausreichende KedRAB-Bestände und Produktionskapazitäten aufrecht

07:54 AM EDT, 17.09.2026 (MT Newswires) -- Kamada (KMDA) hat am Donnerstag bestätigt, dass das Unternehmen über "ausreichende" Bestände und

MT Newswires 17.08.2026 13:52 Uhr

Kamada Aktie News & Nachrichten

Artikel aus der Redaktion der Trader-Zeitung

Kamada hält bei steigender Zahl von Tollwut-Expositionen in den USA ausreichende KedRAB-Bestände und Produktionskapazitäten aufrecht

Kamada senkt quartalsweise Dividende auf 0,17 USD je Aktie; Zahlung am 17. Sept. an am 27. Aug. eingetragene Aktionäre

Kamada-Finanzvorstand Chaime Orlev tritt zurück

Sektor-Update: Gesundheitsaktien am Montagmorgen vorbörslich unverändert bis schwächer

Kamada unterzeichnet Plasma-Liefervertrag über 50 Millionen Dollar mit biopharmazeutischem Unternehmen